Armata Pharmaceuticals earnings release, August 12, 2026

Armata Pharmaceuticals, Inc. (ARMP) · Form 8-K, Item 2.02 · Filed · SEC filing

​

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

​

LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2026, and provided a corporate update.

​

“We continue to finalize activities required to initiate a pivotal Phase 3 superiority study of AP-SA02 in complicated

S. aureus bacteremia in the second half of 2026,” said Dr. Deborah Birx, Chief Executive Officer of Armata. “We recently submitted the Phase 3 protocol to the FDA, responded to the Agency's End-of-Phase 2 meeting minutes, and continued to advance manufacturing, each of these key milestones supporting study initiation. Complicated S. aureus bacteremia is associated with substantial morbidity and mortality, underscoring the need for new treatments. We believe AP-SA02, a novel intravenous phage therapeutic, has the potential to be a valuable and differentiated approach for patients in need.”

​

“We also achieved several additional important milestones for AP-SA02, including FDA agreement on our Agreed Initial Pediatric Study Plan, granting of Fast Track designation by the FDA, and receipt of additional non-dilutive funding from our partners at the U.S. Department of War. We were pleased to promote David House to Chief Financial Officer, ensuring we have the financial leadership in place to execute our late-stage clinical development goals,” concluded Dr. Birx.

​

Second Quarter 2026 and Recent Developments:

​

Clinical, Regulatory, Manufacturing, and Operational Progress

​

Armata has made significant progress across clinical, regulatory, manufacturing, and operational fronts supporting advancement of AP-SA02, the Company’s intravenously administered

Staphylococcus aureus

(“

S. aureus”) multi-phage product candidate, toward a Phase 3 superiority study for adjunct treatment of complicated bacteremia caused by methicillin-sensitive

S. aureus

(“MSSA”) or methicillin-resistant

S. aureus

(“MRSA”). Collectively, these milestones support the planned pivotal Phase 3 superiority study, expected to initiate in the second half of 2026, and designed to support a future Biologics License Application (“BLA”) for AP-SA02.

​

Clinical

​

Chemistry, Manufacturing, and Controls (“CMC”)

​

Key Regulatory Milestones

​

Funding

​

​

Executive Leadership and Corporate Governance

​

​

Publications

​

​

Second Quarter 2026 Financial Results

​

Grant and Award Revenue.

The Company recognized grant and award revenue of $2.5 million for the three months ended June 30, 2026, as compared to $2.2 million in the comparable period in 2025. This represents the Medical Technology Enterprise Consortium’s share of the costs incurred for the Company’s AP-SA02 program for the treatment of SAB.

​

Research and Development.

Research and development expenses for the three months ended June 30, 2026 were approximately $7.6 million, compared to approximately $6.4 million for the comparable period in 2025. The increase primarily reflected higher non-cash stock-based compensation primarily related to option grants issued after the second quarter of 2025.

​

General and Administrative.

General and administrative expenses for the three months ended June 30, 2026 were approximately $5.2 million, compared to approximately $2.6 million for the comparable period in 2025. The increase primarily reflected higher non-cash stock-based compensation primarily related to option grants issued after the second quarter of 2025.

​

Loss from Operations.

Loss from operations for the three months ended June 30, 2026 was approximately $10.3 million, compared to a loss from operations of approximately $6.8 million for the comparable period in 2025. The increase primarily reflected the higher research and development and general and administrative expenses described above, partially offset by higher grant and award revenue.

​

Other Income (Expense).

Other income, net, for the three months ended June 30, 2026 was approximately $84.5 million, compared with other expense, net, of approximately $9.5 million for the comparable period in 2025. Other income in the second quarter of 2026 primarily reflected a $91.0 million non-cash gain from the change in fair value of the Convertible Loan, partially offset by $6.6 million of interest expense.

​

Net Income (Loss).

The net income for the second quarter of 2026 was $74.1 million, or $2.02 earnings per share on a basic basis and a ($0.27) loss per share on a diluted basis, as compared to a net loss of ($16.3) million, or ($0.45) loss per share on a basic and diluted basis, for the comparable period in 2025.

​

Cash and Cash Equivalents.

As of June 30, 2026, Armata held approximately $24.0 million of unrestricted cash and cash equivalents, compared to $8.7 million as of December 31, 2025. The increase primarily reflected the $25.0 million term loan funded in May 2026, approximately $2.4 million of net proceeds under the Company’s at-the-market offering program and approximately $1.2 million of proceeds from stock option exercises, partially offset by cash used in operations.

​

As of August 06, 2026, 37,181,979 common shares were outstanding.

​

About AP-SA02

​

Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated

Staphylococcus aureus bacteremia caused by methicillin-sensitive

S. aureus

(MSSA) or methicillin-resistant

S. aureus

(MRSA). AP-SA02 has received

Qualified Infectious Disease Product (QIDP) and

Fast Track... (truncated)se escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy (“BAT”) compared to BAT alone (placebo) for the treatment of adults with complicated

S. aureus bacteremia.

Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, anticipated to initiate in the second half of 2026.

​

About Armata Pharmaceuticals, Inc.

​

Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for

Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization.

​

Forward Looking Statements

​

Financial statements

Income Statement

Three Months Ended June 30, — (unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Grant and award revenue2,5102,1693,2992,660
Operating expensesResearch and development7,5866,39413,69711,823
Operating expensesGeneral and administrative5,2362,6198,6995,872
Operating expensesTotal operating expenses12,8229,01322,39617,695
Operating expensesOperating loss-10,312-6,844-19,097-15,035
Other income (expense)Interest income69108129167
Other income (expense)Interest expense-6,634-3,808-12,193-7,410
Other income (expense)Change in fair value of the Convertible Loan91,018-5,751-10,044-548
Other income (expense)Total other income (expense), net84,453-9,451-22,108-7,791
Other income (expense)Net income (loss)74,141-16,295-41,205-22,826
Per share information:Net income (loss) per share, basic2.02-0.45-1.12-0.63
Per share information:Weighted average shares outstanding, basic36,747,84036,193,47936,639,66336,189,165
Per share information:Net loss per share, diluted-0.27-0.45-1.12-0.63
Per share information:Weighted average shares outstanding, diluted62,041,70036,193,47936,639,66336,189,165

Balance Sheet

June 30, 2026 — (unaudited)

June 30, 2026December 31, 2025
Current assetsCash and cash equivalents23,9528,688
Current assetsPrepaid expenses and other current assets6731,508
Current assetsOther receivables2,532472
Current assetsTotal current assets27,15710,668
Current assetsProperty and equipment, net11,23012,194
Current assetsOperating lease right-of-use asset32,88433,911
Current assetsIntangible assets, net13,74613,746
Current assetsOther long-term assets4,9336,363
Current assetsTotal assets89,95076,882
Liabilities and stockholders’ deficitAccounts payable, accrued and other current liabilities8,7158,947
Liabilities and stockholders’ deficitConvertible Loan, current163,904
Liabilities and stockholders’ deficitTerm debt, current77,580
Liabilities and stockholders’ deficitTotal current liabilities250,1998,947
Liabilities and stockholders’ deficitConvertible Loan, non-current153,860
Liabilities and stockholders’ deficitTerm debt, non-current42,024103,061
Liabilities and stockholders’ deficitOperating lease liabilities, net of current portion25,82326,533
Liabilities and stockholders’ deficitDeferred tax liability3,0773,077
Liabilities and stockholders’ deficitTotal liabilities321,123295,478
Liabilities and stockholders’ deficitTotal stockholders’ deficit-231,173-218,596
Liabilities and stockholders’ deficitTotal liabilities and stockholders’ deficit89,95076,882

Balance Sheet

Reconciliation of cash, cash equivalents and restricted cash to the consolidated — (unaudited)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash and cash equivalents23,9524,328
Restricted cash4,1205,390
Cash, cash equivalents and restricted cash28,0729,718

Cash Flow

Six Months Ended June 30, — (unaudited)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating activities:Net loss-41,205-22,826
Adjustments required to reconcile net loss to net cash used in operating activities:Depreciation expense1,048743
Adjustments required to reconcile net loss to net cash used in operating activities:Stock-based compensation expense4,4661,356
Adjustments required to reconcile net loss to net cash used in operating activities:Change in fair value of the Convertible Loan10,044548
Adjustments required to reconcile net loss to net cash used in operating activities:Non-cash interest expense12,1837,398
Adjustments required to reconcile net loss to net cash used in operating activities:Change in right-of-use asset1,0271,183
Adjustments required to reconcile net loss to net cash used in operating activities:Changes in operating assets and liabilities:-2,011-3,193
Adjustments required to reconcile net loss to net cash used in operating activities:Net cash used in operating activities-14,448-14,791
Investing activities:Purchases of property and equipment-80-248
Investing activities:Net cash used in investing activities-80-248
Financing activities:Proceeds from issuance of term debt, net of issuance costs25,00010,000
Financing activities:Proceeds from issuance of common stock under ATM, net2,373
Financing activities:Payments for taxes related to net share settlement of equity awards-63-14
Financing activities:Proceeds from exercise of stock options1,212
Financing activities:Net cash provided by financing activities28,5229,986
Financing activities:Net change in cash, cash equivalents and restricted cash13,994-5,053
Financing activities:Cash, cash equivalents and restricted cash, beginning of period14,07814,771
Financing activities:Cash, cash equivalents and restricted cash, end of period28,0729,718
Full release

This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; Armata’s planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the U.S. Securities and Exchange Commission (the “SEC”), including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

​

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

​

Media Contacts:

​

At Armata:

​

Pierre Kyme ir@armatapharma.com

310-665-2928

​

Investor Relations:

​

Joyce Allaire

LifeSci Advisors, LLC jallaire@lifesciadvisors.com

212-915-2569

Armata Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

​

​

​

​

​

​

Armata Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

​

​

​

​

​

​

​

Armata Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

​

​

​ i

Department of War (DoW) award received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Armata Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.